Sinotau and Navidea Sign MOU for Beta-Amyloid Imaging Agent

Beijing 's Sinotau Pharma signed a non-binding MOU with Navidea Biopharma to transfer rights for Navidea's beta-amyloid imaging agent to Cerveau Technologies. Cerveau is a Boston joint venture owned by Sinotau and Canada 's Enigma Biomedical. Currently, Sinotau is suing Navidea. It charges Navidea did not transfer the global rights for the beta-amyloid imaging agent, NAV4694, to Sinotau as previously agreed. In 2014, Navidea in-licensed rights to NAV4694 from AstraZeneca, but later decided to emphasize other projects. More details.... Stock Symbols: (NYSE: NAVB) (NYSE: AZN) Share this with colleagues: // //